Diffuse Toxic Goiter

Etiology

The following are potential and commonly seen causes of goiter development:

• Iodine deficiency [1]
• Autoimmune disorders [2]
• Smoking
• Hereditary pattern [3]
• Medications that include lithium, iodides, and interferon-alpha [4]
• Radiation therapy [5]
• Inflammation and infections, with most recently reported cases after Covid-19 disease as well as vaccination againt Covid virus [6][7]

Epidemiology

Graves disease represents the most common cause of diffuse toxic goiter and remains the leading cause of hyperthyroidism in the United States and worldwide, affecting 1 in 200 individuals. The condition most frequently affects patients between 30 and 50 years of age, although presentation may occur across all age groups. A strong female predominance is observed, with occurrence rates 7 to 10 times higher in females than in males (see Image. Goiter in a Woman). Clinical observations also demonstrate a marked increase in familial incidence, supporting a significant genetic predisposition.

Pathophysiology

Diffuse toxic goiter is a diffusely enlarged vascular gland with a rubber-like consistency. Microscopically, the follicular cells are hypertrophic and hyperplastic, with little colloid present. Lymphocytes and plasma cells infiltrate into the gland and can ultimately aggregate into lymphoid follicles. Not all cases of diffuse toxic goiters are Graves disease, and there may be various nonautoimmune causative processes, although the majority of cases are autoimmune. In Graves disease, antibodies are directed against the thyroid-stimulating hormone receptor, which is expressed on thyroid follicular cells. Chronic stimulation of these receptors leads to increased production of T3 and T4, causing thyroid gland enlargement and eventually a goiter.[8]

Histopathology

This disease demonstrates distinct histological characteristics that define its pathologic appearance. The thyroid gland shows diffuse, non-nodular enlargement accompanied by a smooth capsule and increased vascularity. Microscopic examination reveals hyperplasia of both follicular and papillary cells, along with lymphocytic infiltration within the stromal tissue of the thyroid gland.

Additionally, follicular cell enlargement frequently appears and, in extreme cases, nuclear enlargement may mimic features of papillary thyroid carcinoma. In Graves disease, however, the nuclei typically maintain a rounded configuration with minimal clearing. These overlapping histologic features have generated ongoing controversy regarding a potential association between Graves disease and papillary thyroid carcinoma and whether the coexistence of the 2 conditions alters prognosis. Systematic reviews of multiple studies indicate that papillary carcinoma identified after surgical removal of the thyroid gland carries an excellent prognosis, whereas tumors detected in patients with active Graves disease show outcomes largely determined by local tumor characteristics, including size, extent, margins, and functionality.[9][10]

History and Physical

History

Patients may report a history of 1 or more manifestations associated with a hyperthyroid state. Common symptoms include weight loss, heat intolerance accompanied by polydipsia and excessive sweating, tremors, nervousness, anxiety, fatigue, palpitations, shortness of breath, and frequent defecation with loose stools or diarrhea. Additional complaints may include nausea and vomiting. Local compressive or mass-related symptoms often involve visible neck swelling, a sensation of a lump in the neck, globus sensation, difficulty swallowing, or orthopnea.

Patients with Graves disease may exhibit additional characteristic features, including ophthalmopathy, referred to as Graves orbitopathy, which occurs in approximately 25% of patients and presents with proptosis, diplopia, periorbital edema, and excessive lacrimation. Thyroid dermopathy, a rare manifestation observed in approximately 4% of patients and typically concurrent with orbitopathy, presents as slightly thickened, pigmented skin, most commonly over the pretibial region. Reproductive system abnormalities may also occur, most frequently manifesting as irregular menstruation.[11]

Physical Examination

The most commonly described physical exam findings associated with a patient with diffuse toxic goiter include:

• Constitutional: weight loss
• Head, eyes, ears, neck: neck swelling with occasional audible bruit, proptosis, lid lag, periorbital edema, exophthalmos, stare
• Cardiovascular system: tachycardia, irregular heartbeat, systolic hypertension
• Neuromuscular: tremor of extremities, hyperreflexia, hyperactivity, muscle weakness
• Respiratory system: shortness of breath or tachypnea
• Skin and extremities: moist and warm skin, sweaty hands, pretibial myxedema

Evaluation

The primary evaluation of toxic diffuse goiter involves obtaining a complete thyroid profile, including serum T3, T4, and TSH levels. Serum TSH serves as the most reliable screening test for detecting thyroid hormone excess or deficiency.[12] In patients with diffuse toxic goiter, these tests typically reveal low or marginally low-normal TSH levels, accompanied by elevated peripheral serum thyroid hormone levels.

Evaluation of the underlying cause of thyrotoxicosis may vary depending on population characteristics, socioeconomic factors, and cultural considerations. Clinicians may use radioactive iodide uptake or a combination of thyroid ultrasound with TSH-receptor antibody (TRAb) testing. Diffuse high uptake on radioactive iodine studies indicates Graves disease, as does the presence of an enlarged thyroid gland with positive TRAb results.[11]

Treatment / Management

Treatment of diffuse toxic goiter involves several modalities, including antithyroid drugs, radioactive iodine therapy, and surgical intervention, with selection based on disease severity, patient characteristics, and risk factors.

Antithyroid Drugs

Available antithyroid medications include propylthiouracil, methimazole, and carbimazole. The American Thyroid Association and American Association of Clinical Endocrinology recommend methimazole as the preferred therapy for Graves disease, except in patients with adverse reactions or women in the first trimester of pregnancy. Methimazole offers advantages over propylthiouracil, including higher efficacy, longer half-life and duration of action, and the convenience of once-daily dosing.

Two regimens guide antithyroid drug administration. The titration method gradually reduces the dose to maintain a euthyroid state, while the block-and-replace method combines high-dose antithyroid drugs with thyroxine replacement to achieve and sustain euthyroidism.[13] Recurrence represents a significant limitation of antithyroid drug therapy, particularly within the first year after discontinuation. Studies report a 50% to 55% recurrence risk, with poor prognostic indicators including severe hyperthyroidism, large goiter, elevated T3:T4 ratios, persistently suppressed TSH, and high baseline TRAb levels.[14][15][16] Rare but serious adverse effects include agranulocytosis, hepatotoxicity, and vasculitis. Coadministration of probiotics with antithyroid drug therapy has shown promise in reducing recurrence and flare-ups.[17][18][19](A1)

Radioactive Iodine Therapy

Radioactive iodine therapy (RAI) represents the most common treatment for Graves disease in the United States and demonstrates a high safety and efficacy profile. Absolute contraindications include pregnancy, breastfeeding, and severe uncontrolled thyrotoxicosis, while active moderate to severe Graves orbitopathy constitutes a relative contraindication.[20] Administration may occur via liquid or capsule, and fixed-dose therapy achieves outcomes comparable to calculated-dose therapy based on gland volume and iodine uptake.

Effective RAI therapy requires discontinuation of all iodine-containing medications and adherence to an iodine-restricted diet. Antithyroid drug therapy should be paused, preferably 1 week before RAI, and may resume a few days after administration if needed. Potential adverse effects include hypothyroidism, transient radiation-induced hyperthyroidism, and, rarely, worsening of thyroid-associated ophthalmopathy (TAO). Hypothyroidism is monitored during follow-up, and prednisone may prevent progression of ocular disease. Patients require counseling regarding lifelong monitoring for disease recurrence or hypothyroidism, with prompt treatment offered if abnormalities develop.[15](A1)

Surgery

Thyroidectomy offers the most effective permanent therapy for diffuse toxic goiter, with total thyroidectomy achieving higher success than subtotal thyroidectomy while maintaining similar risk profiles. Surgical intervention serves as a last-line treatment due to risks associated with general anesthesia, recurrent laryngeal nerve injury, vascular complications, and hypothyroidism. Surgery is preferred for patients who cannot tolerate or experience significant adverse effects from antithyroid drugs or RAI therapy, or for those with compressive symptoms resulting from a large goiter.[21](B3)

Differential Diagnosis

Differential diagnoses with similar clinical features of diffuse toxic goiter that should also be considered include:

• Thyrotoxicosis factitia with overprescription or consumption of thyroid hormones
• Subacute or acute thyroiditis
• Multinodular goiter
• TSH-secreting pituitary adenoma
• Iatrogenic iodine supplementation

Prognosis

Patients with diffuse toxic goiter, primarily due to Graves disease, are expected to become hypothyroid during the natural course of their disease regardless of treatment. Prolonged thyrotoxicosis may cause ventricular thickening and, therefore, an increased risk of cardiac morbidity and mortality. Treatment with RAI is conducted with the aim of permanent hypothyroidism, thus making the patient dependent on lifelong thyroid hormone supplementation. Antithyroid drugs have an average remission rate of 50% but an excellent prognosis after 4 years, devoid of relapse.[22]

Complications

The complications that can manifest with diffuse toxic goiter include:

• Hyperthyroidism, or thyroid storm, due to prolonged untreated excess of thyroid hormone
• Cardiac arrhythmias and congestive heart failure
• Rare liver pathology, including fibrosis [23]
• Dermopathy, mostly associated with Graves disease
• Graves ophthalmopathy